Vanguard Asset Management’s AnaptysBio ANAB Stock Holding History

Vanguard Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$654K	Hold	9,690	–	–	﹤0.01%	2080
2026 Q1	$537K	Buy	+9,690	New	+$521K	﹤0.01%	2061

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Asset Management's ANAB Position: Q2 2026 in Review

Vanguard Asset Management held its AnaptysBio (ANAB) position steady in Q2 2026 at 9,690 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Vanguard Asset Management first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Vanguard Asset Management held 9,690 shares of AnaptysBio worth $654K as of Q2 2026.
Vanguard Asset Management left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2080 holding.
Vanguard Asset Management first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
191 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.